Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality
Identifieur interne : 002A13 ( PascalFrancis/Curation ); précédent : 002A12; suivant : 002A14Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality
Auteurs : Georg Bartsch [Autriche] ; Wolfgang Horninger [Autriche] ; Helmut Klocker [Autriche] ; Alexandre Pelzer [Autriche] ; Jasmin Bektic [Autriche] ; Wilhelm Oberaigner [Autriche] ; Harald Schennach [Autriche] ; Georg Schsfer [Autriche] ; Ferdinand Frauscher [Autriche] ; Mathieu Boniol [France] ; Gianluca Severi [Australie] ; Chris Robertson [Royaume-Uni] ; Peter Boyle [France]Source :
- BJU international : (Papier) [ 1464-4096 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Mortalité.
English descriptors
- KwdEn :
Abstract
OBJECTIVE To evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where prostate-specific antigen (PSA) testing was offered for free to all men aged 45-75 years from 1993. SUBJECTS AND METHODS Comparison of prostate cancer mortality rates in Tyrol and the rest of Austria was accomplished through a generalized additive model. A piecewise linear change-point Poisson regression model was used to compare mortality rates in Tyrol and the rest of Austria. Standardized mortality ratios were calculated with reference to the mortality rates in 1986-1990. RESULTS In all, 86.6% of eligible men have been tested at least once since 1993. Cancer deaths in Tyrol in 2005 were 54% (95% confidence interval [Cl] 34-69%) lower than expected compared with 29% (95% Cl 22-35%) in the rest of Austria. The decreasing trend in prostate cancer mortality was significantly greater in Tyrol compared with the rest of Austria (P= 0.001). A significant migration to lower stage disease occurred and radical prostatectomy was associated with low morbidity. CONCLUSIONS In the Tyrol region where treatment is freely available to all patients, where widespread PSA testing and treatment with curative intent occurs, there was a reduction in prostate cancer mortality rates which was significantly greater than the reduction in the rest of Austria. This reduction in prostate cancer mortality is most probably due to early detection, consequent down-staging and effective treatment of prostate cancer.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003633
Links to Exploration step
Pascal:08-0214346Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality</title><author><name sortKey="Bartsch, Georg" sort="Bartsch, Georg" uniqKey="Bartsch G" first="Georg" last="Bartsch">Georg Bartsch</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Horninger, Wolfgang" sort="Horninger, Wolfgang" uniqKey="Horninger W" first="Wolfgang" last="Horninger">Wolfgang Horninger</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Klocker, Helmut" sort="Klocker, Helmut" uniqKey="Klocker H" first="Helmut" last="Klocker">Helmut Klocker</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Pelzer, Alexandre" sort="Pelzer, Alexandre" uniqKey="Pelzer A" first="Alexandre" last="Pelzer">Alexandre Pelzer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Bektic, Jasmin" sort="Bektic, Jasmin" uniqKey="Bektic J" first="Jasmin" last="Bektic">Jasmin Bektic</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Oberaigner, Wilhelm" sort="Oberaigner, Wilhelm" uniqKey="Oberaigner W" first="Wilhelm" last="Oberaigner">Wilhelm Oberaigner</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Tyrol Cancer Registry</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Schennach, Harald" sort="Schennach, Harald" uniqKey="Schennach H" first="Harald" last="Schennach">Harald Schennach</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute of Immunology and Transfusion Medicine, University of Innsbruck</s1><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Schsfer, Georg" sort="Schsfer, Georg" uniqKey="Schsfer G" first="Georg" last="Schsfer">Georg Schsfer</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of Innsbruck</s1><s3>AUT</s3><sZ>8 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Frauscher, Ferdinand" sort="Frauscher, Ferdinand" uniqKey="Frauscher F" first="Ferdinand" last="Frauscher">Ferdinand Frauscher</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Radiology, University of Innsbruck</s1><s3>AUT</s3><sZ>9 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Boniol, Mathieu" sort="Boniol, Mathieu" uniqKey="Boniol M" first="Mathieu" last="Boniol">Mathieu Boniol</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Severi, Gianluca" sort="Severi, Gianluca" uniqKey="Severi G" first="Gianluca" last="Severi">Gianluca Severi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Victoria Cancer Council</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Robertson, Chris" sort="Robertson, Chris" uniqKey="Robertson C" first="Chris" last="Robertson">Chris Robertson</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Strathclyde University and Health Protection Scotland</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>12 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Boyle, Peter" sort="Boyle, Peter" uniqKey="Boyle P" first="Peter" last="Boyle">Peter Boyle</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0214346</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0214346 INIST</idno><idno type="RBID">Pascal:08-0214346</idno><idno type="wicri:Area/PascalFrancis/Corpus">003633</idno><idno type="wicri:Area/PascalFrancis/Curation">002A13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality</title><author><name sortKey="Bartsch, Georg" sort="Bartsch, Georg" uniqKey="Bartsch G" first="Georg" last="Bartsch">Georg Bartsch</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Horninger, Wolfgang" sort="Horninger, Wolfgang" uniqKey="Horninger W" first="Wolfgang" last="Horninger">Wolfgang Horninger</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Klocker, Helmut" sort="Klocker, Helmut" uniqKey="Klocker H" first="Helmut" last="Klocker">Helmut Klocker</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Pelzer, Alexandre" sort="Pelzer, Alexandre" uniqKey="Pelzer A" first="Alexandre" last="Pelzer">Alexandre Pelzer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Bektic, Jasmin" sort="Bektic, Jasmin" uniqKey="Bektic J" first="Jasmin" last="Bektic">Jasmin Bektic</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Oberaigner, Wilhelm" sort="Oberaigner, Wilhelm" uniqKey="Oberaigner W" first="Wilhelm" last="Oberaigner">Wilhelm Oberaigner</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Tyrol Cancer Registry</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Schennach, Harald" sort="Schennach, Harald" uniqKey="Schennach H" first="Harald" last="Schennach">Harald Schennach</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute of Immunology and Transfusion Medicine, University of Innsbruck</s1><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Schsfer, Georg" sort="Schsfer, Georg" uniqKey="Schsfer G" first="Georg" last="Schsfer">Georg Schsfer</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of Innsbruck</s1><s3>AUT</s3><sZ>8 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Frauscher, Ferdinand" sort="Frauscher, Ferdinand" uniqKey="Frauscher F" first="Ferdinand" last="Frauscher">Ferdinand Frauscher</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Radiology, University of Innsbruck</s1><s3>AUT</s3><sZ>9 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Boniol, Mathieu" sort="Boniol, Mathieu" uniqKey="Boniol M" first="Mathieu" last="Boniol">Mathieu Boniol</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Severi, Gianluca" sort="Severi, Gianluca" uniqKey="Severi G" first="Gianluca" last="Severi">Gianluca Severi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Victoria Cancer Council</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Robertson, Chris" sort="Robertson, Chris" uniqKey="Robertson C" first="Chris" last="Robertson">Chris Robertson</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Strathclyde University and Health Protection Scotland</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>12 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Boyle, Peter" sort="Boyle, Peter" uniqKey="Boyle P" first="Peter" last="Boyle">Peter Boyle</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country></affiliation></author></analytic><series><title level="j" type="main">BJU international : (Papier)</title><title level="j" type="abbreviated">BJU int. : (Print)</title><idno type="ISSN">1464-4096</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">BJU international : (Papier)</title><title level="j" type="abbreviated">BJU int. : (Print)</title><idno type="ISSN">1464-4096</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Early stage</term><term>Epidemiology</term><term>Incidence</term><term>Mortality</term><term>Nephrology</term><term>Prognosis</term><term>Project</term><term>Prostate cancer</term><term>Treatment</term><term>Urology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la prostate</term><term>Projet</term><term>Stade précoce</term><term>Pronostic</term><term>Incidence</term><term>Epidémiologie</term><term>Mortalité</term><term>Traitement</term><term>Néphrologie</term><term>Urologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Mortalité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">OBJECTIVE To evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where prostate-specific antigen (PSA) testing was offered for free to all men aged 45-75 years from 1993. SUBJECTS AND METHODS Comparison of prostate cancer mortality rates in Tyrol and the rest of Austria was accomplished through a generalized additive model. A piecewise linear change-point Poisson regression model was used to compare mortality rates in Tyrol and the rest of Austria. Standardized mortality ratios were calculated with reference to the mortality rates in 1986-1990. RESULTS In all, 86.6% of eligible men have been tested at least once since 1993. Cancer deaths in Tyrol in 2005 were 54% (95% confidence interval [Cl] 34-69%) lower than expected compared with 29% (95% Cl 22-35%) in the rest of Austria. The decreasing trend in prostate cancer mortality was significantly greater in Tyrol compared with the rest of Austria (P= 0.001). A significant migration to lower stage disease occurred and radical prostatectomy was associated with low morbidity. CONCLUSIONS In the Tyrol region where treatment is freely available to all patients, where widespread PSA testing and treatment with curative intent occurs, there was a reduction in prostate cancer mortality rates which was significantly greater than the reduction in the rest of Austria. This reduction in prostate cancer mortality is most probably due to early detection, consequent down-staging and effective treatment of prostate cancer.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1464-4096</s0></fA01><fA03 i2="1"><s0>BJU int. : (Print)</s0></fA03><fA05><s2>101</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality</s1></fA08><fA11 i1="01" i2="1"><s1>BARTSCH (Georg)</s1></fA11><fA11 i1="02" i2="1"><s1>HORNINGER (Wolfgang)</s1></fA11><fA11 i1="03" i2="1"><s1>KLOCKER (Helmut)</s1></fA11><fA11 i1="04" i2="1"><s1>PELZER (Alexandre)</s1></fA11><fA11 i1="05" i2="1"><s1>BEKTIC (Jasmin)</s1></fA11><fA11 i1="06" i2="1"><s1>OBERAIGNER (Wilhelm)</s1></fA11><fA11 i1="07" i2="1"><s1>SCHENNACH (Harald)</s1></fA11><fA11 i1="08" i2="1"><s1>SCHSFER (Georg)</s1></fA11><fA11 i1="09" i2="1"><s1>FRAUSCHER (Ferdinand)</s1></fA11><fA11 i1="10" i2="1"><s1>BONIOL (Mathieu)</s1></fA11><fA11 i1="11" i2="1"><s1>SEVERI (Gianluca)</s1></fA11><fA11 i1="12" i2="1"><s1>ROBERTSON (Chris)</s1></fA11><fA11 i1="13" i2="1"><s1>BOYLE (Peter)</s1></fA11><fA14 i1="01"><s1>Department of Urology, University of Innsbruck</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="02"><s1>Tyrol Cancer Registry</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></fA14><fA14 i1="03"><s1>Institute of Immunology and Transfusion Medicine, University of Innsbruck</s1><s3>AUT</s3><sZ>7 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Pathology, University of Innsbruck</s1><s3>AUT</s3><sZ>8 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Radiology, University of Innsbruck</s1><s3>AUT</s3><sZ>9 aut.</sZ></fA14><fA14 i1="06"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></fA14><fA14 i1="07"><s1>Victoria Cancer Council</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></fA14><fA14 i1="08"><s1>Strathclyde University and Health Protection Scotland</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>12 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>Tyrol Prostate Cancer Screening Group</s1><s3>INC</s3></fA17><fA20><s1>809-816</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>1050</s2><s5>354000183342850050</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>39 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0214346</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>BJU international : (Papier)</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>OBJECTIVE To evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where prostate-specific antigen (PSA) testing was offered for free to all men aged 45-75 years from 1993. SUBJECTS AND METHODS Comparison of prostate cancer mortality rates in Tyrol and the rest of Austria was accomplished through a generalized additive model. A piecewise linear change-point Poisson regression model was used to compare mortality rates in Tyrol and the rest of Austria. Standardized mortality ratios were calculated with reference to the mortality rates in 1986-1990. RESULTS In all, 86.6% of eligible men have been tested at least once since 1993. Cancer deaths in Tyrol in 2005 were 54% (95% confidence interval [Cl] 34-69%) lower than expected compared with 29% (95% Cl 22-35%) in the rest of Austria. The decreasing trend in prostate cancer mortality was significantly greater in Tyrol compared with the rest of Austria (P= 0.001). A significant migration to lower stage disease occurred and radical prostatectomy was associated with low morbidity. CONCLUSIONS In the Tyrol region where treatment is freely available to all patients, where widespread PSA testing and treatment with curative intent occurs, there was a reduction in prostate cancer mortality rates which was significantly greater than the reduction in the rest of Austria. This reduction in prostate cancer mortality is most probably due to early detection, consequent down-staging and effective treatment of prostate cancer.</s0></fC01><fC02 i1="01" i2="X"><s0>002B14D02</s0></fC02><fC02 i1="02" i2="X"><s0>002B20B02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Cancer de la prostate</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Prostate cancer</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Cáncer de la próstata</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Projet</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Project</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Proyecto</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Stade précoce</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Early stage</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Estadio precoz</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Pronostic</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Prognosis</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Pronóstico</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Incidence</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Incidence</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Incidencia</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Epidémiologie</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Epidemiology</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Epidemiología</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Mortalité</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Mortality</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Mortalidad</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Néphrologie</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Nephrology</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Nefrología</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Urologie</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Urology</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Urología</s0><s5>17</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Male genital diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital macho patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Urinary system disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Aparato urinario patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la prostate</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0><s5>40</s5></fC07><fN21><s1>140</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002A13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:08-0214346
|texte= Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality
}}
| This area was generated with Dilib version V0.6.33. |  |